Capricor Therapeutics Inc. stocks have been trading up by 87.27 percent amid bullish sentiment on its lead cardiac therapy.
Click Here for a Millionaire's POV on Trading CAPR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Peer‑reviewed results from Capricor’s pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy, published in The Lancet, showed a 54% slowing of upper limb disease progression and concurrent cardiac benefits in a largely non‑ambulatory DMD population, validating the trial design and statistical methods.
- Capricor’s lead therapy deramiocel (CAP‑1002) has an active BLA under FDA review with a PDUFA action date of 2026/08/22, supported by the HOPE‑3 Phase 3 data now independently validated in The Lancet.
- Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight from Neutral and raised its price target sharply to $28 from $3.50, while Oppenheimer reiterated an Outperform rating and sees attractive risk‑reward after a roughly 70% share price decline ahead of the AdCom.
- The company is disputing aspects of the FDA’s AdCom briefing documents, arguing that agency staff used an outdated statistical analysis plan even though HOPE‑3 met its primary endpoint under the finalized version and showed statistically significant benefits on upper limb function and cardiac outcomes.
- Capricor reported Q2 2026 with no revenue and a widening loss as it prepares for potential commercialization of deramiocel, but says its roughly $238M in cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months, while moderating commercial spend pending regulatory clarity.
Live Update At 08:32:53 EDT: On Friday, August 14, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 87.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CAPR has turned into a classic biotech rollercoaster. On the daily chart, Capricor Therapeutics slid from the high‑teens around late July down into the mid‑single digits after the FDA advisory drama, then based between about $3.80 and $4.40. That’s a massive reset in expectations in just a few weeks.
Recently, CAPR has started to stabilize. The last several daily closes cluster tight around $4.00–$4.20. Tight ranges after a big dump often signal traders are waiting on the next catalyst rather than bailing out. For short‑term trading, that $4 area is now the clear battleground.
Intraday, the 5‑minute tape shows CAPR doing what momentum biotech names do best: big swings. Pre‑market levels around $7.00–$9.00 show heavy volatility and fast reversals. That kind of price action tells traders that algos and headline‑driven players are active, and liquidity is decent for day trades, but risk per candle is high.
More Breaking News
- Sandisk Stock Soars As AI Storage And Growth Outlook Ignite Rally
- SMR Stock Grinds Higher As NuScale Locks In Key Contracts
- CAPR Stock Draws Traders As Lancet Data And Big Upgrade Hit
- ESTC Stock Climbs As AI Security Wins Battle Analyst Downgrade
Fundamentally, Capricor Therapeutics is a pre‑revenue story. The latest report shows a net loss of about $34M for the quarter and negative operating cash flow near $29M, typical for a late‑stage biotech gearing up for launch. Yet CAPR still carries roughly $278M in cash and short‑term investments and sports a current ratio around 8.4, which means near‑term bills are not the issue; the binary FDA outcome on deramiocel is. With price‑to‑book under 1, the market is discounting that asset heavily, which is exactly the kind of setup active traders track into big regulatory dates.
Why Traders Are Watching CAPR Now
Traders are circling CAPR because the story has all the ingredients they look for: a binary FDA catalyst, heavy volatility, and now high‑profile validation of the science. Capricor Therapeutics locked in a major credibility win when The Lancet published peer‑reviewed HOPE‑3 Phase 3 results showing deramiocel slowed upper limb decline by 54% versus placebo and helped the heart in late‑stage Duchenne muscular dystrophy patients. For a tiny biotech, getting into The Lancet with positive Phase 3 data is a big deal. It tells the market the trial design and statistics have passed an external smell test.
Those data already underpin an active BLA for deramiocel, with the FDA’s PDUFA decision date set for 2026/08/22. CAPR is effectively a one‑drug story into that date. That’s why the earlier negative advisory vote on the cardiomyopathy piece and the dispute over how FDA staff analyzed the numbers rocked the stock. Capricor Therapeutics has pushed back hard, saying regulators leaned on an outdated statistical analysis plan and that the final SAP version clearly supports a win on the upper‑limb endpoint.
Wall Street is now openly split, which fuels trading. B. Riley has taken the cautious lane, cutting its target down to $5 and sticking with Neutral. On the other side, Cantor Fitzgerald just upgraded Capricor Therapeutics to Overweight and hiked its target to $28 from $3.50. Oppenheimer remains in the bullish camp too, reiterating Outperform and calling the roughly 70% drop ahead of the AdCom an attractive risk‑reward skew.
Add in Capricor’s roughly $238M cash pile, paused non‑core programs, and moderated commercial spending, and CAPR becomes a pure FDA and headline trade through the next year. That concentration of risk is exactly what momentum and catalyst‑driven traders specialize in.
Conclusion
For active traders, CAPR is not a sleepy biotech to tuck away; it is a live‑wire catalyst play. Capricor Therapeutics has late‑stage, peer‑reviewed data in The Lancet, an active BLA, and a clear 2026/08/22 PDUFA clock. The HOPE‑3 trial met its primary upper‑limb endpoint, and those results are now locked into the public scientific record. That is powerful ammunition in any ongoing debate with the FDA over statistics and trial interpretation.
At the same time, the Q2 2026 numbers remind everyone what’s at stake. Capricor Therapeutics still has no product revenue, a widening loss, and heavy R&D and operating spend. The balance sheet looks solid for at least 12 months thanks to that ~$238M cash war chest, but CAPR is essentially a single‑asset bet. If deramiocel stumbles, the current price‑to‑book “discount” may not look cheap at all. If the drug gets approved, the stock’s prior high‑teens price zone may not be the ceiling.
For now, analyst sentiment is split but tilting constructive, with Cantor’s $28 target and Oppenheimer’s Outperform battling B. Riley’s caution. That tension is what drives big intraday ranges and sharp squeezes when headlines break. As Tim Sykes likes to hammer home, “Volatility is opportunity, but only if you respect risk and cut losses quickly.” CAPR fits that description perfectly. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. Traders who apply that mindset to CAPR—logging how they trade the spikes, the fades, and the quiet consolidations—can turn this volatile biotech into a real‑time trading classroom. Traders studying the chart, the Lancet data, and the regulatory calendar have a textbook case study in how binary biotech catalysts reshape price action, sentiment, and trading setups.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.